A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 301–400 of 1,018
Pharmacokinetics and drug interactions of eslicarbazepine acetate
Bialer, M., & Soares‐da‐Silva, P. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03519.x · Cited by 168
“In the past decade, a biopharmaceutic classification system (BCS) has been established to categorize drugs according to their water solubility and ability to pass across membranes (Amidon et al., 1995; Wu & Benet, 2005; Rowland & Tozer, 2010).”
BackgroundRecent advances in nanotechnology-based drug delivery systems for the kidney
Oroojalian, F., Charbgoo, F., Hashemi, M., Amani, A., Yazdian-Robati, R., Mokhtarzadeh, A., Ramezani, M., & Hamblin, M. R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.027 · Cited by 168
Fundamental aspects of DMPK optimization of targeted protein degraders
Cantrill, C., Chaturvedi, P., Rynn, C., Petrig Schaffland, J., Walter, I., & Wittwer, M. B. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.012 · Cited by 162
The road map to oral bioavailability: an industrial perspective
Thomas, V. H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C. L., & El-Kattan, A. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.591 · Cited by 168
“Therefore, drug flux is a product of drug permeability and solubility [17].”
BackgroundTreenate, P., & Monvisade, P. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.02.061 · Cited by 166
Sunesen, V. H., Pedersen, B. L., Kristensen, H. G., & Müllertz, A. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.11.007 · Cited by 169
Sjögren, E., Westergren, J., Grant, I., Hanisch, G., Lindfors, L., Lennernäs, H., Abrahamsson, B., & Tannergren, C. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.019 · Cited by 168
“It is commonly classified as a BCS Class II drug owing to its low aqueous solubility and high permeability (Peff = 4.3).”
InfluentialSelf-citationRole of surfactant and pH on dissolution properties of fenofibrate and glipizide—A technical note
Jamzad, S., & Fassihi, R. (2006) · AAPS PharmSciTech · doi:10.1208/pt070233 · Cited by 164
“In most cases, however, better correlation between dissolution and bioavailability have been achieved when sink conditions have prevailed.(8)”
BackgroundNanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles
Wais, U., Jackson, A. W., He, T., & Zhang, H. (2016) · Nanoscale · doi:10.1039/c5nr07161e · Cited by 164
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development
Gadade, D. D., & Pekamwar, S. S. (2016) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2016.062 · Cited by 160
Essential oil–cyclodextrin complexes: an updated review
Wadhwa, G., Kumar, S., Chhabra, L., Mahant, S., & Rao, R. (2017) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-017-0744-2 · Cited by 161
Dahan, A., & Amidon, G. L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800088f · Cited by 163
Self-citationDiscovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, E. J., Braun, M.-G., Heald, R. A., MacLeod, C., Chan, C., Clausen, S., Edgar, K. A., Eigenbrot, C., Elliott, R., Endres, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01422 · Cited by 158
Carvedilol dissolution improvement by preparation of solid dispersions with porous silica
Planinšek, O., Kovačič, B., & Vrečer, F. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.035 · Cited by 164
Sharma, P., & Garg, S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.019 · Cited by 165
Passerini, N., Albertini, B., Perissutti, B., & Rodriguez, L. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.028 · Cited by 162
Rahman, M. S., Roy, R., Jadhav, B., Hossain, M. N., Halim, M. A., & Raynie, D. E. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114745 · Cited by 164
Oehlke, K., Adamiuk, M., Behsnilian, D., Gräf, V., Mayer-Miebach, E., Walz, E., & Greiner, R. (2014) · Food & Function · doi:10.1039/c3fo60067j · Cited by 163
Novel Furosemide Cocrystals and Selection of High Solubility Drug Forms
Goud, N. R., Gangavaram, S., Suresh, K., Pal, S., Manjunatha, S. G., Nambiar, S., & Nangia, A. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22805 · Cited by 162
Sievens-Figueroa, L., Bhakay, A., Jerez-Rozo, J. I., Pandya, N., Romañach, R. J., Michniak-Kohn, B., Iqbal, Z., Bilgili, E., & Davé, R. N. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.001 · Cited by 161
Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement
Stuurman, F. E., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0040-2 · Cited by 161
“3 Strategies to Enhance the Bioavailability 3.1 Pharmaceutical Strategies For poorly water-soluble drugs with a good permeability (BCS class 2), the dissolution rate is often the limiting step for absorption.”
MethodInfluentialVarma, M. V., Gardner, I., Steyn, S. J., Nkansah, P., Rotter, C. J., Whitney-Pickett, C., Zhang, H., Di, L., Cram, M., Fenner, K. S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2004912 · Cited by 164
Vandecruys, R., Peeters, J., Verreck, G., & Brewster, M. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.006 · Cited by 163
Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery
Ting, J., Porter, W., Mecca, J. M., Bates, F. S., & Reineke, T. M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00646 · Cited by 176
Sánchez-Félix, M., Burke, M., Chen, H. H., Patterson, C., & Mittal, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.009 · Cited by 162
Nicolaides, E., Galia, E., Efthymiopoulos, C., Dressman, J. B., & Reppas, C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018959511323 · Cited by 165
Larregieu, C. A., & Benet, L. Z. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9456-8 · Cited by 158
“Since the inception of the Biopharmaceutics Classification System (BCS), which originally demonstrated a relationship between the human jejunal permeability rate of a drug and its extent of absorption (2), the US FDA has supported waivers of in vivo bioavailability and bioequivalence studies to facilitate the drug app…”
Tronde, A., Nordén, B. O., Marchner, H., Wendel, A., Lennernäs, H., & Bengtsson, U. H. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10386 · Cited by 158
Self-citationEnhancement of dissolution rate of piroxicam using liquisolid compacts
Javadzadeh, Y., Siahi-Shadbad, M. R., Barzegar-Jalali, M., & Nokhodchi, A. (2005) · Il Farmaco · doi:10.1016/j.farmac.2004.09.005 · Cited by 161
Orally Active Peptides: Is There a Magic Bullet?
Räder, A. F. B., Weinmüller, M., Reichart, F., Schumacher‐Klinger, A., Merzbach, S., Gilon, C., Hoffman, A., & Kessler, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807298 · Cited by 161
Dodoo, A., Bansal, S. S., Barlow, D. J., Bennet, F., Hider, R. C., Lansley, A. B., Lawrence, M. J., & Marriott, C. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200002)89:2<199::aid-jps7>3.0.co;2-b · Cited by 18
Self-citationDesign of Potent Amorphous Drug Nanoparticles for Rapid Generation of Highly Supersaturated Media
Matteucci, M. E., Brettmann, B. K., Rogers, T. L., Elder, E. J., Williams, R. O., & Johnston, K. P. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700211 · Cited by 162
Novel extraction, rapid assessment and bioavailability improvement of quercetin: A review
Manzoor, M. F., Hussain, A., Sameen, A., Sahar, A., Khan, S., Siddique, R., Aadil, R. M., & Xu, B. (2021) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2021.105686 · Cited by 173
Solid-state characterization of rifampicin samples and its biopharmaceutic relevance
Agrawal, S., Ashokraj, Y., Bharatam, P. V., Pillai, O., & Panchagnula, R. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.02.011 · Cited by 162
Pharmacokinetics and metabolism in early drug discovery
Smith, D. A., & Waterbeemd, H. V. D. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80056-8 · Cited by 160
Papich, M. G., & Martinez, M. N. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9743-7 · Cited by 181
Cryoprotectants for freeze drying of drug nano-suspensions: Effect of freezing rate
Lee, M. K., Kim, M. Y., Kim, S., & Lee, J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21786 · Cited by 161
Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal
Zhang, J., Lv, H., Jiang, K., & Gao, Y. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.023 · Cited by 159
Current Methods for Predicting Human Food Effect
Lentz, K. A. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9025-8 · Cited by 159
“Wu and Benet suggest food effect can be anticipated on the basis of both solubility and permeability as described by the Biopharmaceutics Classification System (BCS) (13,14).”
BackgroundNovel strategies for the formulation and processing of poorly water-soluble drugs
Göke, K., Lorenz, T., Repanas, A., Schneider, F., Steiner, D., Baumann, K., Bunjes, H., Dietzel, A. H., Finke, J. H., Glasmacher, B., et al. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.05.008 · Cited by 172
Yuan, Y., Cui, Y., Zhang, L., Zhu, H.-P., Guo, Y.-S., Zhong, B., Hu, X., Zhang, L., Wang, X., & Chen, L. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.054 · Cited by 160
Cheng, L., & Wong, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070672 · Cited by 161
“The inception of the biopharmaceutics classification system (BCS) drug classes has revolutionized the regulation of therapeutics worldwide [8].”
BackgroundAn Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS)
Truzzi, F., Tibaldi, C., Zhang, Y., Dinelli, G., & D’Amen, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115514 · Cited by 172
Encapsulation in cyclodextrins to widen the applications of essential oils
Kfoury, M., Auezova, L., Greige‐Gerges, H., & Fourmentin, S. (2018) · Environmental Chemistry Letters · doi:10.1007/s10311-018-0783-y · Cited by 167
Saravanakumar, A., Sadighi, A., Ryu, R. J., & Akhlaghi, F. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00750-8 · Cited by 165
Natural halloysite nanotubes as mesoporous carriers for the loading of ibuprofen
Tan, D., Yuan, P., Bergaya, F., Yu, H., Liu, D., Liu, H., & He, H. (2013) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2013.05.007 · Cited by 158
Goss, S. L., Lemons, K. A., Kerstetter, J. E., & Bogner, R. H. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.11.0004 · Cited by 154
“…Classification System categorizes drugs based on the solubility and permeability in order to aid in determining a drug’s potential for development (Amidon et al 1995), with Class I representing drugs high in both categories and Class IV representing drugs relatively low in both categories.”
BackgroundKell, D. B., & Oliver, S. G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00231 · Cited by 156
“The Biopharmaceutics Classification System (BCS), based on the work of Amidon and colleagues (e.g., Amidon et al., 1995; Dahan et al., 2009; Chen et al., 2011), was developed to indicate a “bioequivalence,” and divides drugs into four classes based on their solubility and presumed (human jejunal)…”
MethodLennernäs, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.016 · Cited by 171
Self-citationKalantzi, L., Persson, E., Polentarutti, B., Abrahamsson, B., Goumas, K., Dressman, J. B., & Reppas, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0207-8 · Cited by 159
“Drug concentration at the gut wall is a function of the dose, the intralumenal solubility, and the intralumenal dissolution/release kinetics (1).”
BackgroundPrediction of human absorption of natural compounds by the non-everted rat intestinal sac model
Ruan, L.-P., Chen, S., Yu, B., Zhu, D.-N., CORDELL, G. A., & Qiu, S. X. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.01.013 · Cited by 164
Inhaled Medicines: Past, Present, and Future
Anderson, S. D., Atkins, P. J., Bäckman, P., Cipolla, D. C., Clark, A., Daviskas, E., Disse, B. G., Entcheva‐Dimitrov, P., Fuller, R. W., Gonda, I., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000108 · Cited by 167
Rozehnal, V., Nakai, D., Hoepner, U., Fischer, T., Kamiyama, E., Takahashi, M., Yasuda, S., & Mueller, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.02.025 · Cited by 156
Mechanochemistry: A Green Approach in the Preparation of Pharmaceutical Cocrystals
Solares-Briones, M., Coyote-Dotor, G., Páez-Franco, J. C., Zermeño-Ortega, M. R., Contreras, C. M. D. L. O., Canseco‐González, D., Avila‐Sorrosa, A., Morales‐Morales, D., & Germán-Acacio, J. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060790 · Cited by 164
“This protocol classifies drugs in four groups: Class I (high solubility and permeability); Class II (low solubility and high permeability); Class III (high solubility and low permeability); and Class IV (low solubility and permeability) [26,27].”
BackgroundPredicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties
Gu, C., Li, H., Levons, J. K., Lentz, K. A., Gandhi, R. B., Raghavan, K. S., & Smith, R. L. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9236-1 · Cited by 158
“It is interesting to note that the food effect category is separated by dose number 50 rather than the value 250 used in BCS classification (27).”
MethodZhou, L., Yang, L., Tilton, S., & Wang, J. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20913 · Cited by 155
In silico prediction of ADME and pharmacokinetics
Boobis, A. R., Gundert‐Remy, U., Kremers, P. G., Macheras, P. E., & Pelkonen, O. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00185-9 · Cited by 156
Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review
LaFountaine, J. S., McGinity, J. W., & Williams, R. O. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0393-y · Cited by 163
“It has been reported that up to 70% of investigational new drugs (1) and up to 40% of marketed drugs (2) exhibit poor aqueous solubility and fall into class II or IV of the Biopharmaceutics Classification System (3).”
BackgroundKarmwar, P., Graeser, K. A., Gordon, K. C., Strachan, C. J., & Rades, T. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.019 · Cited by 154
Drug mechanochemical activation
Colombo, I., Grassi, G., & Grassi, M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21733 · Cited by 154
An in vitro toolbox to accelerate anti-malarial drug discovery and development
Charman, S. A., Andreu, A., Barker, H., Blundell, S., Campbell, A., Campbell, M., Chen, G., Chiu, F. C. K., Crighton, E., Katneni, K., et al. (2020) · Malaria Journal · doi:10.1186/s12936-019-3075-5 · Cited by 149
“5 have not been determined, these compounds cannot strictly be classified according to either the Biopharmaceutics Classification System (BCS [33]) or the Biopharmaceutics Drug Disposition Classification System (BDDCS [63]).”
BackgroundResultCheng, C.-L., Yu, L., Lee, H.-L., Yang, C.-Y., Lue, C.-S., & Chou, C. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.03.016 · Cited by 156
Buckley, S. T., Fischer, S. M., Fricker, G., & Brandl, M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.12.007 · Cited by 179
Döring, B., & Petzinger, E. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.882353 · Cited by 135
Sun, D. D., Wen, H., & Taylor, L. S. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.03.024 · Cited by 160
Nanonization techniques to overcome poor water-solubility with drugs
Da Silva, F. L. O., Marques, M. B. D. F., Kato, K. C., & Carneiro, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1750591 · Cited by 136
“class IV drugs are considered the worst cases, even unsuitable for being utilized in dosage forms [7,12,13].”
BackgroundBreda, S. A., Jimenez-Kairuz, A. F., Manzo, R. H., & Olivera, M. E. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.12.026 · Cited by 152
“Introduction The Biopharmaceutics Classification System (BCS) is a scientific ramework for classifying drug substances based upon their aqueus solubilities related to dose at three relevant pHs and intestinal ermeability (Amidon et al., 1995).”
BackgroundKennedy, M. T., Hu, J., Gao, P., Li, L., Ali-Reynolds, A., Chal, B., Gupta, V., Ma, C., Mahajan, N., Akrami, A., et al. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800061r · Cited by 152
Blume, H. H., & Schug, B. S. (1999) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(99)00076-7 · Cited by 152
Sassene, P. J., Knopp, M. M., Hesselkilde, J. Z., Koradia, V., Larsen, A. T., Rades, T., & Müllertz, A. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22226 · Cited by 151
“An increasing number of active pharmaceutical ingredients (APIs) are poorly water soluble, but have a high permeability and are therefore classified as class 2 drugs according to the Biopharmaceutics Classification System (BCS).(1) For these BCS class 2 drugs the bioavailability from traditional dosage forms, for exam…”
BackgroundAvdeef, A., & Testa, B. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012496 · Cited by 151
Shah, V. P., & Amidon, G. L. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9620-9 · Cited by 150
Self-citationSoft Gelatin Capsules (Softgels)
Gullapalli, R. P. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22151 · Cited by 150
“Compounds belonging to class II and class IV of the Biopharmaceutics Classification System (BCS) show extremely low aqueous solubility throughout the physiological pH range, resulting in low and inconsistent bioavailability.(53) However, when such a compound demonstrates enhanced solubility in a nonaqueous vehicle, so…”
BackgroundOxidized Mesoporous Silicon Microparticles for Improved Oral Delivery of Poorly Soluble Drugs
Wang, F., He, H. Z., Barnes, T. J., Barnett, C., & Prestidge, C. A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900221e · Cited by 150
Greco, K., & Bogner, R. H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23025 · Cited by 150
Drug delivery strategies for poorly water-soluble drugs: the industrial perspective
van Hoogevest, P., Liu, X., & Fahr, A. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.614228 · Cited by 171
“The DCS and BCS classify oral drug substances for solubility in water and permeation properties.”
BackgroundInfluentialMDR1 Genotype-related Pharmacokinetics: Fact or Fiction?
Sakaeda, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.391 · Cited by 160
Incorporating small molecules or biologics into nanofibers for optimized drug release: A review
Sebe, I., Szabó, P., Kállai-Szabó, B., & Zelkó, R. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.054 · Cited by 149
“…is facing an increasing prevalence of undesirable physicochemical properties and consequent unfavourable biopharmaceutical behaviour of active agents, resulting in a progressively declining number of drug approvals of small molecules (Allison, 2012; Amidon et al., 1995; Hann and Keseru, 2012).”
BackgroundParticle design of poorly water-soluble drug substances using supercritical fluid technologies
Yasuji, T., Takeuchi, H., & Kawashimà, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.025 · Cited by 149
Physicochemical and drug-delivery considerations for oral drug bioavailability
Chan, O. H., & Stewart, B. H. (1996) · Drug Discovery Today · doi:10.1016/1359-6446(96)10039-8 · Cited by 149
Cell Culture Models of the Respiratory Tract Relevant to Pulmonary Drug Delivery
Steimer, A., Haltner, E., & Lehr, C. (2005) · Journal of Aerosol Medicine · doi:10.1089/jam.2005.18.137 · Cited by 158
Bachar, M., Mandelbaum, A. D., Portnaya, I., Perlstein, H., Even‐Chen, S., Barenholz, Y., & Danino, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.004 · Cited by 154
Jantratid, E., Maio, V. D., Ronda, E., Mattavelli, V., Vertzoni, M., & Dressman, J. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.03.015 · Cited by 148
“There are many studies demonstrating different aspects of IVIVC for products containing BCS Class II compounds housed in immediate-release (IR) dosage forms ( Amidon et al., 1995; Dressman and Reppas, 2000; Wei and Lobenberg, 2006; Sunesen et al., 2005) and for modified-release (MR) dosage forms in general (Kortejarvi…”
BackgroundKataoka, M., Masaoka, Y., Yamazaki, Y., Sakane, T., Sezaki, H., & Yamashita, S. (2003) · Pharmaceutical Research · doi:10.1023/a:1026107906191 · Cited by 148
“The importance of GI transit time to consider drug absorption was well described in the theory presented by Amidon et al. (1, 2 ), where the average transit time in the small intestine was defined as 3 h (20).”
BackgroundRecent advances in improving oral drug bioavailability by cocrystals
Emami, S., Siahi‐Shadbad, M., Adibkia, K., & Barzegar-Jalali, M. (2018) · Bioimpacts · doi:10.15171/bi.2018.33 · Cited by 161
“(B) Plot of absorption rate versus dissolution rate of meloxicam and 12 meloxicam cocrystals (1-12).”
BackgroundCirri, M., Maestrini, L., Maestrelli, F., Mennini, N., Mura, P., Ghelardini, C., & Mannelli, L. D. C. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1529209 · Cited by 161
“Owing to its low solubility and permeability (Basant Kumar Reddy & Karunakar, 2011), HCT is ranked as a BCS class IV drug (Amidon et al., 1995), and presents problems of poor and variable bioavailability (Patel et al., 1984).”
BackgroundBiorelevant dissolution media as a predictive tool for glyburide a class II drug
Wei, H., & Löbenberg, R. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.05.004 · Cited by 164
“Based493 on the BCS (Amidon et al., 1995), glyburide is a typical494 class II drug, which has high permeability and low aqueous495 solubility.496 3.5.”
BackgroundInfluentialSheng, J. J., Kasim, N. A., Ramachandran, C., & Amidon, G. L. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.06.006 · Cited by 148
Self-citationIn vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets
Shoukri, R. A., Ahmed, I. S., & Shamma, R. N. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.04.005 · Cited by 147
Morgen, M. M., Bloom, C., Beyerinck, R., Bello, A., Song, W., Wilkinson, K. F., Steenwyk, R. C., & Shamblin, S. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0558-7 · Cited by 147
“The oral absorption of low-solubility, high-permeability BCS Class II compounds, in particular, is often limited (4,5).”
BackgroundNano and microparticle engineering of water insoluble drugs using a novel spray-drying process
Schafroth, N., Arpagaus, C., Jadhav, U. Y., Makne, S., & Douroumis, D. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.09.038 · Cited by 161
The Use of BDDCS in Classifying the Permeability of Marketed Drugs
Benet, L. Z., Amidon, G. L., Barends, D. M., Lennernäs, H., Polli, J. E., Shah, V. P., Stavchansky, S. A., & Yu, L. X. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9523-x · Cited by 147
“Based on the work of Amidon and colleagues (1) the FDA promulgated the guidance for waiver of in vivo bioavailability and bioequivalence testing of immediate-release solid dosage forms for drugs that are Biopharmaceutics Classification System (BCS) Class 1 high-solubility, high-permeability, when such drug products al…”
Self-citationRefining stability and dissolution rate of amorphous drug formulations
Grohganz, H., Priemel, P. A., Löbmann, K., Nielsen, L. H., Laitinen, R., Müllertz, A., den Mooter, G. V., & Rades, T. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.911728 · Cited by 155
“These drugs are classified as class 2 and class 4 in the biopharmaceutics classification system (BCS), respectively [1].”
BackgroundFabrication of quercetin nanocrystals: Comparison of different methods
Kakran, M., Shegokar, R., Sahoo, N. G., Shaal, L. A., Li, L., & Müller, R. H. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.006 · Cited by 147
Patterson, J. E., James, M. B., Forster, A. H., Lancaster, R. W., Butler, J., & Rades, T. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20424 · Cited by 147
Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits
Attia, I. A., El‐Gizawy, S. A., Fouda, M. A., & Donia, A. M. (2007) · AAPS PharmSciTech · doi:10.1208/pt0804106 · Cited by 146
Rapid Identification of P-glycoprotein Substrates and Inhibitors
Chang, C. K., Bahadduri, P. M., Polli, J. E., Swaan, P. W., & Ekins, S. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012351 · Cited by 148
“The biopharmaceutics classification system has been used as a helpful guide to classify compounds based on their aqueous solubility and gastrointestinal permeability (Amidon et al., 1995).”
MethodEngineering of Pharmaceutical Materials: An Industrial Perspective
Chow, K., Tong, H. H. Y., Lum, S., & Chow, A. H. L. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21212 · Cited by 146
In Vitro–In Vivo Correlation: Importance of Dissolution in IVIVC
Cardot, J.-M., Beyssac, E., & Alric, M. (2007) · Dissolution Technologies · doi:10.14227/dt140107p15 · Cited by 148
Multiple Peaking Phenomena in Pharmacokinetic Disposition
Davies, N. M., Takemoto, J. K., Brocks, D. R., & Yáñez, J. A. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319320-000000000-00000 · Cited by 161
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.